Biotech Azitra Backs Rash and Rare-Skin Trials, Awaits 2026 Data

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ — Azitra, Inc. (“Azitra”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update. FY 2025 and Recent Business Highlights Initiated Phase 1/2 Trial for ATR-04 program targeting oncology patients with EGFRi-associated …

Biotech Azitra backs rash and rare-skin trials, awaits 2026 data

Azitra raised $8.5M in 2025 while posting an $11M net loss and $2.1M cash, as it targets 2026 topline data from ATR-12 and ATR-04 trials.